RWE 101 – 4 Potential Uses for Improving Drug Development
Real world evidence (RWE) refers to data collected outside the context of traditional clinical trials, such as observational studies, registries, and electronic health records. RWE can provide valuable insights into the safety, effectiveness, and real-world use of drugs, and has the potential to transform drug development.
Some of the opportunities of real world evidence in drug development include:
1. Improved patient recruitment: RWE can help identify patient populations that are typically underrepresented in clinical trials, such as elderly patients, patients with multiple comorbidities, and those with rare diseases. This can help improve patient recruitment and enable more representative clinical trials.
2. Enhance clinical trial design: RWE can help inform the design of clinical trials, for example, by identifying appropriate endpoints, understanding patient demographics, and identifying potential confounding factors that need to be accounted for.
Identify safety concerns: RWE can help identify safety concerns that may not have been detected in clinical trials, especially those related to long-term use or rare adverse events. This can help improve post-marketing surveillance and ensure that drugs are used safely in the real world.
3. Better understanding of effectiveness: RWE can provide insights into the effectiveness of drugs in the real world, including how drugs are used in combination with other treatments, and how patient outcomes vary across different subpopulations.
4. Accelerate drug development: By leveraging RWE, drug development timelines can be accelerated as fewer resources are required for clinical trials, making it easier to conduct larger and more complex studies. Additionally, RWE can help optimize the design of clinical trials, reducing the likelihood of failed trials and resulting in faster regulatory approvals.
In summary, real world evidence has the potential to improve drug development in a number of ways, including patient recruitment, clinical trial design, safety monitoring, and accelerating drug development timelines. By leveraging RWE, drug developers can gain a better understanding of how drugs work in the real world, which can ultimately improve patient outcomes.
Share this story...
Real World Evidence (RWE) 101 – NICE Real World Evidence Framework
RWE 101 - NICE Real World Evidence Framework The UK's National Institute for Health and Care Excellence (NICE) has developed a Real World Evidence (RWE) Framework to help evaluate [...]
Real World Evidence (RWE) 101 – The Role of RWE in Health Technology Assessments (HTAs)
RWE 101 - The Role of RWE in Health Technology Assessments (HTAs) Real-world evidence (RWE) is becoming increasingly important in the context of health technology assessment (HTA), which is [...]
Real World Evidence (RWE) 101 – Verifying the Source of Data (Not to be Confused with Source Data Verification…Yup! Confusing!)
RWE 101 - Verifying the Source of Data (Not to be Confused with Source Data Verification...Yup! Confusing!) Verifying the source of data is critical in the context of real [...]
Real World Evidence (RWE) 101 – Challenges in RWE Generation (Regulatory Grade RWE?)
RWE 101 - Challenges in RWE Generation (Regulatory Grade RWE?) Real-world evidence (RWE) refers to data derived from real-world sources such as electronic health records, claims data, and patient-generated [...]
Real World Evidence (RWE) 101 – Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations
RWE 101 - Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations Real-world evidence (RWE) studies include observational studies that uses data collected in real-world settings to [...]
Real World Evidence (RWE) 101 – Acknowledgement of the Limitations of Clinical Trials and RWE Studies
RWE 101 - Acknowledgement of the Limitations of Clinical Trials and RWE Studies Clinical trials are experiments designed to test the safety and efficacy of new treatments or [...]








